Faga Daniel
President, CEO at ANAB; EVP, Chief Operating Officer at Mirati Therapeutics, Inc.; Chief Business Officer at Spark Therapeutics, Inc.
- Sold, on record
- $9.4M
- Dollars the filings state
- Form 4 sales
- 15
- Latest Mar 27, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- ANABANAPTYSBIO, INCPresident, CEO
- Mirati Therapeutics, Inc.EVP, Chief Operating Officer
- Spark Therapeutics, Inc.Chief Business Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ANAB212,277 shares
- Spark Therapeutics, Inc.30,000 shares
- Mirati Therapeutics, Inc.3,965 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Mirati Therapeutics, Inc.Plan not statedJan 7, 2021 2021
Sold 2,625 shares at $216.33 ($568k)
Faga Daniel, EVP, Chief Operating Officer
Sold 10% of holdings ($5.7M position)23,615 shares leftFirst sale on recordFiling
- 2 Form 4 sale Mirati Therapeutics, Inc.Plan not statedFeb 2, 2021 +26 days
Sold 1,340 shares at $194.38 ($260k)
Faga Daniel, EVP, Chief Operating Officer
Sold 4.2% of holdings ($6.2M position)30,638 shares leftFiling
- 3 Form 4 sale ANABNo planJan 8, 2024 +1070 days
Sold 6,866 shares at $21.81 ($150k)
Faga Daniel, CEO
No 10b5-1 planSold 0.8% of holdings ($19.7M position)898,027 shares leftFirst sale on recordFiling
- 4 Form 4 sale ANABNo planMar 25, 2024 +77 days
Sold 148,940 shares at $22.75 ($3.4M)
Faga Daniel, CEO
No 10b5-1 planSold 16.6% of holdings ($20.4M position)749,087 shares leftFiling
- 5 Form 4 sale ANABNo planJan 5, 2026 +651 days
Sold 15,309 shares at $43.26 ($662k)
Faga Daniel, President, CEO
No 10b5-1 planSold 3.2% of holdings ($20.5M position)458,139 shares leftFiling
- 6 Form 4 sale ANABNo planJan 7, 2026 +2 days
Sold 9,202 shares at $45.11 ($415k)
Faga Daniel, President, CEO
No 10b5-1 planSold 1.9% of holdings ($21.5M position)466,787 shares left0.6x usual sizeFiling
- 7 Form 4 sale ANABNo planJan 8, 2026 +1 day
Sold 14,281 shares at $44.71 ($639k)
Faga Daniel, President, CEO
No 10b5-1 planSold 2.9% of holdings ($22.1M position)479,344 shares left0.9x usual sizeFiling
- 8 Form 4 sale ANABNo planMar 27, 2026 +78 days
Sold 17,679 shares at $61.61 ($1.1M)
Faga Daniel, President, CEO
No 10b5-1 planSold 3.4% of holdings ($31.6M position)495,965 shares left1.2x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (15)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | Mar 27, 2026 | ANAB | President, CEO | Form 4 sale | 17,679 | $1.1M | 3.4% | No plan | SEC |
| Jan 8, 2026 | Jan 9, 2026 | ANAB | President, CEO | Form 4 sale | 14,281 | $639k | 2.9% | No plan | SEC |
| Jan 7, 2026 | Jan 8, 2026 | ANAB | President, CEO | Form 4 sale | 9,202 | $415k | 1.9% | No plan | SEC |
| Jan 5, 2026 | Jan 6, 2026 | ANAB | President, CEO | Form 4 sale | 15,309 | $662k | 3.2% | No plan | SEC |
| Mar 25, 2024 | Mar 26, 2024 | ANAB | CEO | Form 4 sale | 148,940 | $3.4M | 16.6% | No plan | SEC |
| Jan 8, 2024 | Jan 9, 2024 | ANAB | CEO | Form 4 sale | 6,866 | $150k | 0.8% | No plan | SEC |
| Feb 2, 2021 | Feb 3, 2021 | Mirati Therapeutics, Inc. | EVP, Chief Operating Officer | Form 4 sale | 1,340 | $260k | 4.2% | Plan not stated | SEC |
| Jan 7, 2021 | Jan 8, 2021 | Mirati Therapeutics, Inc. | EVP, Chief Operating Officer | Form 4 sale | 2,625 | $568k | 10.0% | Plan not stated | SEC |
| Oct 24, 2017 | Oct 24, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 7,500 | $607k | 100.0% | Unusual | SEC |
| Sep 19, 2017 | Sep 20, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 1,500 | $128k | 100.0% | Unusual | SEC |
| Sep 12, 2017 | Sep 14, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 6,000 | $495k | 100.0% | Unusual | SEC |
| Sep 7, 2017 | Sep 11, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 3,000 | $255k | 100.0% | Unusual | SEC |
| Jul 24, 2017 | Jul 26, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 3,000 | $210k | 100.0% | Unusual | SEC |
| Jun 29, 2017 | Jun 29, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 4,500 | $282k | 100.0% | Unusual | SEC |
| May 15, 2017 | May 17, 2017 | Spark Therapeutics, Inc. | Chief Business Officer | Form 4 sale | 4,500 | $256k | 100.0% | Unusual | SEC |